Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

被引:46
作者
Arriazu, Elena [1 ]
Pippa, Raffaella [2 ]
Odero, Maria D. [1 ,3 ,4 ]
机构
[1] Univ Navarra, Ctr Appl Med Res CIMA, Hematol Oncol Program, E-31080 Pamplona, Spain
[2] Univ Dundee, Ctr Gene Regulat & Express, Dundee, Scotland
[3] Univ Navarra, Dept Biochem & Genet, E-31080 Pamplona, Spain
[4] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain
关键词
PP2A; SET; AML; FTY720; OP449; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR PP2A; REGULATORY SUBUNIT B55-ALPHA; TYROSINE KINASE INHIBITORS; A-BETA-SUBUNIT; BREAST-CANCER; C-MYC; COMMON EVENT; SET-CAN; CIP2A;
D O I
10.3389/fonc.2016.00078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.
引用
收藏
页数:11
相关论文
共 118 条
[41]   PP2A:B56ε, a Substrate of Caspase-3, Regulates p53-dependent and p53-independent Apoptosis during Development [J].
Jin, Zhigang ;
Wallace, Lindsay ;
Harper, Scott Q. ;
Yang, Jing .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (45) :34493-34502
[42]   CIP2A inhibits PP2A in human malignancies [J].
Junttila, Melissa R. ;
Puustinen, Pietri ;
Niemela, Minna ;
Ahola, Raija ;
Arnold, Hugh ;
Bottzauw, Trine ;
Ala-aho, Risto ;
Nielsen, Christina ;
Ivaska, Johanna ;
Taya, Yoichi ;
Lu, Shi-Long ;
Lin, Shujun ;
Chan, Edward K. L. ;
Wang, Xiao-Jing ;
Grenman, Reidar ;
Kast, Juergen ;
Kallunki, Tuula ;
Sears, Rosalie ;
Kahari, Veli-Matti ;
Westermarck, Jukka .
CELL, 2007, 130 (01) :51-62
[43]   Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia:: Evidence for a pathogenic role of NPAT, CUL5 and PPP2R1B [J].
Kalla, Claudia ;
Scheuermann, Markus O. ;
Kube, Ina ;
Schlotter, Magdalena ;
Mertens, Daniel ;
Doehner, Hartmut ;
Stilgenbauer, Stephan ;
Lichter, Peter .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (08) :1328-1335
[44]   The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin [J].
Kalousi, Alkmini ;
Hoffbeck, Anne-Sophie ;
Selemenakis, Platonas N. ;
Pinder, Jordan ;
Savage, Kienan I. ;
Khanna, Kum Kum ;
Brino, Laurent ;
Dellaire, Graham ;
Gorgoulis, Vassilis G. ;
Soutoglou, Evi .
CELL REPORTS, 2015, 11 (01) :149-163
[45]   Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937 [J].
Kandilci, A ;
Mientjes, E ;
Grosveld, G .
LEUKEMIA, 2004, 18 (02) :337-340
[46]   Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer [J].
Kelly, Lindsey M. ;
Barila, Guillermo ;
Liu, Pengyuan ;
Evdokimova, Viktoria N. ;
Trivedi, Sumita ;
Panebianco, Federica ;
Gandhi, Manoj ;
Carty, Sally E. ;
Hodak, Steven P. ;
Luo, Jianhua ;
Dacic, Sanja ;
Yu, Yan P. ;
Nikiforova, Marina N. ;
Ferris, Robert L. ;
Altschuler, Daniel L. ;
Nikiforov, Yuri E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (11) :4233-4238
[47]   Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target [J].
Khanna, Anchit ;
Pimanda, John E. ;
Westermarck, Jukka .
CANCER RESEARCH, 2013, 73 (22) :6548-6553
[48]   MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer [J].
Khanna, Anchit ;
Bockelman, Camilla ;
Hemmes, Annabrita ;
Junttila, Melissa R. ;
Wiksten, Jan-Patrik ;
Lundin, Mikael ;
Junnila, Siina ;
Murphy, Daniel J. ;
Evan, Gerard I. ;
Haglund, Caj ;
Westermarck, Jukka ;
Ristimaki, Ari .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (11) :793-805
[49]   Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55α regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt [J].
Kuo, Yi-Chun ;
Huang, Kai-Yun ;
Yang, Chung-Hsiang ;
Yang, Yu-San ;
Lee, Wen-Yu ;
Chiang, Chi-Wu .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (04) :1882-1892
[50]   A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-Iα in integrating chromatin hypoacetylation and transcriptional repression [J].
Kutney, SN ;
Hong, R ;
Macfarlan, T ;
Chakravarti, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (29) :30850-30855